{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:09:43Z","timestamp":1790633383739,"version":"4.1.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12879-017-2755-4","type":"journal-article","created":{"date-parts":[[2017,9,30]],"date-time":"2017-09-30T04:52:30Z","timestamp":1506747150000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["A dual regimen of ritonavir\/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48\u00a0weeks\u2019 observational data"],"prefix":"10.1186","volume":"17","author":[{"given":"Amedeo F.","family":"Capetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Vittoria","family":"Cossu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Orofino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetana","family":"Sterrantino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Cenderello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe V.","family":"De Socio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Cattelan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Soria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Rusconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niccol\u00f2","family":"Riccardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Maria","family":"Baldin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fosca P.","family":"Niero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Barbarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliano","family":"Rizzardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,9,30]]},"reference":[{"issue":"3","key":"2755_CR1","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3851\/IMP3109","volume":"22","author":"AF Capetti","year":"2017","unstructured":"Capetti AF, Sterrantino G, Cossu MV, Cenderello G, Cattelan AM, De Socio GV, et al. Correction: Correction: Salvage therapy or simplification of salvage regimens with dolutegravir plus ritonavir-boosted darunavir dual therapy in highly cART-experienced subjects: an Italian cohort. Antivir Ther. 2017;22(3):273\u20135. doi: \n10.3851\/IMP3109\n\n. Epub 2016 Nov 28","journal-title":"Antivir Ther"},{"key":"2755_CR2","unstructured":"Dual Therapy With Boosted Darunavir + Dolutegravir (Dualis) \nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT02486133\n\n Accessed 4 April, 2017."},{"issue":"4","key":"2755_CR3","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1179\/1945577115Y.0000000001","volume":"16","author":"KT Tashima","year":"2015","unstructured":"Tashima KT, Mollan KR, Na L, Gandhi RT, Klingman KL, Fichtenbaum CJ, et al. Regimen selection in the OPTIONS trial of HIV salvage therapy: drug resistance, prior therapy, and race\u2013ethnicity determine the degree of regimen complexity. HIV Clin Trials. 2015;16(4):147\u201356.","journal-title":"HIV Clin Trials"},{"issue":"12","key":"2755_CR4","doi-asserted-by":"crossref","first-page":"908","DOI":"10.7326\/M15-0949","volume":"163","author":"KT Tashima","year":"2015","unstructured":"Tashima KT, Smeaton LM, Fichtenbaum CJ, Andrade A, Eron JJ, Gandhi RT, et al. HIV salvage therapy does not require nucleoside reverse transcriptase inhibitors: a randomized trial. Ann Intern Med. 2015;163(12):908\u201317.","journal-title":"Ann Intern Med"},{"issue":"2","key":"2755_CR5","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/QAI.0000000000001193","volume":"74","author":"GD Huhn","year":"2017","unstructured":"Huhn GD, Tebas P, Gallant J, Wilkin T, Cheng A, Yan M, et al. A randomized, open-label trial to evaluate switching to elvitegravir\/cobicistat\/emtricitabine\/tenofovir alafenamide plus darunavir in treatment-experienced HIV-1 infected adults. J Acquir Immune Defic Syndr. 2017;74(2):193\u2013200.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2755_CR6","first-page":"220","volume":"17","author":"J Pasquau","year":"2015","unstructured":"Pasquau J, Hidalgo-Tenorio C. Nuke-Sparing Regimens for the Long-Term Care of HIV Infection. AIDS Rev. 2015;17:220\u201330.","journal-title":"AIDS Rev"},{"issue":"4","key":"2755_CR7","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1373\/clinchem.2006.077180","volume":"53","author":"AS Levey","year":"2007","unstructured":"Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, Kusek JW, et al. Chronic Kidney Disease Epidemiology Collaboration. Expressing the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate with Standardized Serum Creatinine Values. Clin Chem. 2007;53(4):766\u201372.","journal-title":"Clin Chem"},{"key":"2755_CR8","unstructured":"CTCAE website. Available: \nhttp:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/About.html\n\n. Accessed 21 February 2017."},{"issue":"11","key":"2755_CR9","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s40262-013-0093-2","volume":"52","author":"ML Cottrell","year":"2013","unstructured":"Cottrell ML, Hadzic T, Kashuba ADM. Clinical Pharmacokinetic, Pharmacodynamic and Drug-Interaction Profile of the Integrase Inhibitor Dolutegravir. Clin Pharmacokinet. 2013;52(11):981\u201394.","journal-title":"Clin Pharmacokinet"},{"key":"2755_CR10","doi-asserted-by":"publisher","unstructured":"Cattaneo D, Minisci D, Cozzi V, Riva A, Meraviglia P, Clementi E, et al. Dolutegravir plasma concentrations according to companion antiretroviral drug: unwanted drug interaction or desirable boosting effect? Antivir Ther. 2016; doi: \n10.3851\/IMP3119\n\n. [Epub ahead of print]","DOI":"10.3851\/IMP3119"},{"issue":"1","key":"2755_CR11","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/hiv.12468","volume":"18","author":"C Hoffmann","year":"2017","unstructured":"Hoffmann C, Welz T, Sabranski M, et al. Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients. HIV Med. 2017;18(1):56\u201363.","journal-title":"HIV Med"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-017-2755-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,9,30]],"date-time":"2017-09-30T04:52:38Z","timestamp":1506747158000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-017-2755-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,30]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["2755"],"URL":"https:\/\/doi.org\/10.1186\/s12879-017-2755-4","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,30]]},"article-number":"658"}}